Suggested remit: To appraise the clinical and cost effectiveness of lifileucel within its marketing authorisation for previously treated unresectable or metastatic melanoma.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
STA Standard
|
| ID number |
3863
|
Provisional Schedule
| Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3863 |
24 July 2024 - 21 August 2024 |
Project Team
| Project lead |
Emily Richards |
Email enquiries
|
Date
|
Update
|
|
24 July 2024
|
In progress. Scoping commenced. |
|
01 May 2024
|
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late November 2024.
|
|
16 January 2024
|
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late August 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late October 2024. |
|
03 April 2023
|
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Lifileucel for previously treated unresectable or metastatic melanoma have been revised. It is anticipated that the appraisal will begin in late-May 2024 when we will write to you about how you can get involved. |
|
02 December 2022
|
Please note that following an update received from the company this appraisal is still to be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available during second half 2023. |
|
30 March 2021
|
Please note that following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual